Introduction
By integrating cellular metabolism, membrane potential (V m ), and excitability, ATPsensitive K + (K ATP ) channels carry out fundamental roles in nerve, muscle, epithelial, and endocrine tissue physiology (Ashcroft, 1988) . K ATP channels are octomeric complexes of four pore-forming Kir6.x inward rectifier K + (Kir) channel subunits and four regulatory SURx sulfonylurea receptor subunits (Nichols CG, 2006) . Kir6.1 (KCNJ8), Kir6.2 (KCNJ11), and SUR1 (ABCC8) are encoded by different genes; SUR2A and SUR2B (ABCC9) are splice variants of the same gene. The three major channel subtypes created by different subunit combinations exhibit distinctive biophysical, regulatory, and pharmacological properties, as well as cell type-specific expression (Flagg et al., 2010; Hibino et al., 2010; Nichols et al., 2013) .
Pancreatic islet β-cell K ATP channels are validated drug targets for type 2 diabetes and severe hypoglycemia resulting from excessive insulin secretion (Denton and Jacobson, 2012) .
Increases in blood glucose induce MgATP-dependent Kir6.2/SUR1 channel inhibition, V m depolarization, Ca 2+ influx through L-type voltage-dependent Ca 2+ channels (VDCC), and secretion of insulin, which, in turn, acts on a myriad of target tissues to promote glucose uptake and utilization (Ashcroft, 2007) . Sulfonylurea drugs (e.g. glibenclamide, tolbutamide) that directly inhibit Kir6.2/SUR1 and stimulate insulin secretion are used clinically to help manage glycemic levels in type 2 diabetic patients. In contrast, K ATP channel activators (e.g. diazoxide)
are used to treat disorders of severe hypoglycemia, such as congenital hyperinsulinism and insulin-producing pancreatic tumors (Ashcroft, 2007; Nichols et al., 2007) . The major K ATP channel subtype in cardiomyocytes consists of Kir6.2 and SUR2A (Nichols et al., 2013) , and potassium channel opener (KCO) activation of sarcolemmal K ATP channels and Vm hyperpolarization affords cardioprotection from subsequent ischemia-reperfusion injury (Grover M  O  L  #  9  1  8  8  4   6 and Garlid, 2000) . Activation of vascular smooth muscle Kir6.1/SUR2B with pinacidil or diazoxide leads to vasodilation and a reduction in blood pressure (Flagg et al., 2010) , but can also result in pathological edema and other cardiovascular pathologies reminiscent of those found in Cantu syndrome, which results from gain-of-function mutations in SUR2 (Nichols et al., 2013) .
Given the broad tissue distribution of K ATP channels, their important physiological roles, and therapeutic as well as pathological potential in various conditions, there is considerable interest in the continued development of pharmacological modulators for targeting specific subtypes of K ATP channels (Hansen, 2006) . Here, we report the serendipitous discovery of a novel xanthine derivative that directly activates heterologously expressed Kir6.2/SUR1 channels and native pancreatic β-cell K ATP channels. The activator, termed VU0071063, is more potent and efficacious than diazoxide and is selective for SUR1-containing K ATP channels. VU0071063
represents a new tool compound for interrogating Kir6.2/SUR1 channel physiology and structure-function relationships of K ATP channel gating.
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Materials and Methods

Expression vectors
The following vectors were used in this study: pcDNA5/TO-Kir6.2 (NM_010602), pcDNA5/TO-Kir6.1 (NM_004982), pcDNA3.1-SUR1 (L40623.1), pCMV6c-SUR2A (D83598.1), pcDNA3.1-SUR2B (D86038.2), pcDNA5/TO-Kir2.1 (NM_000891.2), pcDNA5/TO-Kir2.2 (NM_021012), pcDNA5/TO-Kir2.3 (NM_152868).
Cell lines and transfections
T-REx-HEK293 cells were transfected with pcDNA5/TO-Kir6.2 using Lipofectamine 2000 (Life Technologies) and cultured with Blasticidin and Hygromycin to select stably transfected cells as previously described (Lewis et al., 2009; Raphemot et al., 2011) . After confirming they exhibited tetracycline-inducible Kir6.2 expression by Western blot analysis (Supplemental Fig. 1 ), the cells were co-transfected with pcDNA3.1-SUR1 and grown in G418-containing medium to select cells carrying stably integrated plasmids for both K ATP channel subunits. Monoclonal lines were isolated by limiting dilution, expanded, and tested for tetracycline-inducible thallium (Tl + ) flux, as described below. One cell line exhibiting robust Tl 
Calcium imaging
Islet-cell intracellular calcium ([Ca 2+ ] i ) was measured using Ca 2+ sensitive dye fura-2 (Life Technologies) as previously described (Jacobson et al., 2007) . Briefly, mouse islets were dissociated in 0.005% trypsin, plated on glass coverslips, and cultured for 16 h in RPMI-1640 medium supplemented with 10% fetal calf serum (FCS), concentrations of glucose specified, 100
IU ml−1 penicillin, and 100 mg ml−1 streptomycin. Cells were dye-loaded for 20 min at 37°C
with 2 μM fura-2-AM in solution containing (in mM): 119 NaCl, 2. 
Measurement of complex II activity
Mitochondria were isolated from four mouse hearts using differential centrifugation in sucrose-based buffer as previously described (Wojtovich et al., 2011) (Wojtovich and Brookes, 2008) . Complex II enzymatic activity was measured spectrophotometrically at 600 nm as previously described (Wojtovich and Brookes, 2008; Wojtovich and Brookes, 2009 ).
Results
Serendipitous discovery of the Kir6.2/SUR1 activator VU0071063
A Tl + flux assay of Kir6.2/SUR1 K ATP channels was developed to assess the specificity of inhibitors of a mosquito Kir channel identified in a high-throughput screen (Raphemot, Denton, unpublished). The assays employ stably transfected T-REx-HEK293 cells expressing Kir6.2 from a tetracycline-inducible promoter and SUR1 constitutively (Supplemental Fig. 1 ). 
Kir6.2/SUR1 is inhibited in T-
Effects of VU0071063 on pancreatic Kir6.2/SUR1 K ATP channels
The activity of VU0071063 on Kir6.2/SUR1 was compared to diazoxide and the SUR2- This article has not been copyedited and formatted. The final version may differ from this version. 
Whole-cell patch clamp electrophysiology was used to further characterize the effects of VU0071063 and diazoxide on Kir6.2/SUR1. Bath application of VU0071063 rapidly (Fig. 3A) and dose-dependently ( Fig. 3C ) activated Kir6.2/SUR1 currents, with a maximal activation of 1077 ± 87% at a dose of 50 μM. In contrast, diazoxide activated Kir6.2/SUR1 more slowly ( Fig.   3B ) and with significantly (T-test P = 0.01) lower efficacy (maximal activation 580 ± 105% at 50 μM) than VU0071063. As shown in Fig. 3B , following steady-state activation with 50 μM diazoxide, bath addition of 50 μM VU0071063 led to further Kir6.2/SUR1 activation. These data show that at low micromolar concentrations, VU0071063 is a more potent activator of Kir6.2/SUR1 than diazoxide.
To exclude the possibility that VU0071063 might be activating channels in intact cells by altering cell metabolism, currents were recorded from COSm6 cells expressing Kir6.2 and SUR1, This article has not been copyedited and formatted. The final version may differ from this version. in inside-out membrane patches. In the presence of 0.1 mM MgATP, which inhibits WT channels ~90%, both 10 μM and 20 μM of VU0071063 markedly increased the patch current (Supplemental Fig. 2 ).
VU0071063 is selective SUR1-containing K ATP channels
The pharmacological selectivity of known K ATP channel agonists is achieved through interactions with the SUR subunit. To determine if VU0071063 activity is also dependent on the SUR, we tested its effects on Kir6.2 or Kir6.1 channels containing SUR1 or SUR2A using patch clamp electrophysiology. Diazoxide and pinacidil were used as positive controls for SUR1-and SUR2A-containting channels, respectively. As shown in the representative timecourse experiment in Fig. 4A , and summary data (mean ± SEM; n = 7) in Fig. 4C , bath application of 50 μM VU0071063 rapidly and reversibly activated Kir6.2/SUR1 to a greater extent than an equal concentration of diazoxide. Qualitatively similar results were observed in cells transfected with Kir6.1/SUR1 (Fig. 4D) . In striking contrast, VU0071063 had no effect on Kir6.2/SUR2A ( Fig   4B, 4E) Fig. 5 ). Activation of β-cell K ATP channels with VU0071063 in the presence of high (14 mM) glucose resulted in inhibition of β-cell Ca 2+ influx and reduction in Ca 2+ levels back to those observed in low (2 mM) glucose conditions (green cells, Fig. 5 ). The reduction in Ca 2+ influx mediated via K ATP activation is reversible following removal of VU0071063, which results in a return of β-cell Ca 2+ levels to high (14mM) glucose levels (red cells, Fig. 5 ). This data indicates that VU0071063 activates native β-cell K ATP channels and thereby reduces VDCC activation and Ca 2+ influx.
Kir6.2/SUR1 activation by VU0071063 is not mediated by a PDE inhibitory pathway
Vascular smooth muscle K ATP channels are activated by cAMP/PKA-and cGMP/PKGdependent pathways following phosphodiesterase (PDE) inhibition with theophylline (see discussion). Because VU0071063 contains a theophylline moiety (Supplemental Fig. 4A ), we tested whether theophylline could activate Kir6.2/SUR1 in Tl + flux assays under conditions identical to those used to discover VU0071063. However, as shown in Supplemental Fig. 4B , theophylline at a concentration of 250 μM had no effect on Kir6.2/SUR1-dependent Tl + flux.
This article has not been copyedited and formatted. The final version may differ from this version. (IC 50 = 91 μM)(Supplemental Fig. 5 ). Patch clamp electrophysiology was used to determine whether VU0071063 acts on the voltage-gated K + channel Kv2.1, which contributes to action repolarization in pancreatic β-cells (Philipson et al., 1994; Roe et al., 1996) . Cells were voltage clamped at a holding potential of -75 mV and stepped to +50 mV every 5 seconds. Bath application of 10 μM VU0071063 led to a 7.8 ± 0.9 % (n = 4) reduction in outward Kv2.1 current at 40 mV that was fully reversible (Supplemental Fig. 6 ).
This article has not been copyedited and formatted. The final version may differ from this version. although VU0071063 does not activate SUR2A-containing channels, potential effects on SUR2B-containing channels and hence vascular smooth muscle tone should be considered before using VU0071063 as an in vivo probe of SUR1-containing K ATP channels. Despite several attempts and different experimental conditions, we were unable to measure the activity of SUR2B-containing K ATP channels in our expression system and could not determine the effect of VU0071063 on these channels (unpublished observations).
VU0071063 is structurally related to the xanthine derivative KMUP-1, which induces smooth muscle relaxation and vasodilation through activation of the cGMP and cAMP pathways. membrane potential in its mechanism of action (Dai et al., 2010; Lin et al., 2002; Wu et al., 2001 (Kubo et al., 1994) . The PDE-inhibitory activity of KMUP-1 is likely mediated through the theophylline moiety, since the addition of theophylline, a non-specific PDE inhibitor, recapitulates the effects of KMUP-1 on cGMP levels and vascular tone (Wu et al., 2004) . As noted earlier, VU0071063 also contains a theophylline group, raising the possibility that PDE inhibition and cGMP or cAMP accumulation contributes to Kir6.2/SUR1 activation. However, theophylline at a concentration of 250 μM had no effect on Kir6.2/SUR1-mediated Tl + flux following 20-min incubation. This, together with the observation that VU0071063 directly activates Kir6.2/SUR1 in excised membrane patches (Supplemental Fig. 2 ), suggests that PDE inhibition and cyclic nucleotides are not essential components of its mechanism of action.
There are several important questions regarding VU0071063 and its mechanism of action remaining to be answered. KMUP-1 and VU0071063 differ only in the structure of their sidechains that project off a common theophylline moiety, yet only VU0071063 appears to be a direct SUR1/Kir6.2 channel activator. Determination of VU0071063 structure-activity relationships with medicinal chemistry will inform a deeper understanding of pharmacophore requirements for activation of SUR1-and SUR2-containing K ATP channels and may lead to the development of improved xanthine-based activators. Do VU0071063 and diazoxide activate Grimmsmann and Rustenbeck, 1998), which has made it difficult to ascribe beneficial and undesirable effects of the drug to K ATP channel-mediated effects or other mechanisms.
Importantly, VU0071063 (< 100 µM) had no effect on complex II activity (Supplemental Table   1 ). It will be important to determine whether VU0071063 action is limited to plasma membrane SUR1-containing channels or also has off-target effects on mitochondrial respiration and potentially other signaling pathways. The activation of K ATP channels are linked to signaling pathways that can protect a cellular against stress (Wojtovich et al., 2013) . While the location of the channel that mediates protection (e.g. canonical surface K ATP vs. mitochondrial K ATP channels) remains elusive (Sato et al., 2000; Suzuki et al., 2002; Wojtovich et al., 2013) , VU0071063 may prove to be a valuable tool to investigate the role of K ATP channels in stress responses.
In conclusion, VU0071063 is a novel xanthine derivative that directly and selectively activates K ATP channels containing SUR1. Despite K ATP channels being validated drug targets for numerous diseases, VU0071063 is only the third SUR1-preferring chemotype discovered using small-molecule library screening. We anticipate that the Tl + flux assay described here will enable the discovery of additional small-molecule modulators of Kir6.2/SUR1 and other K ATP channel subtypes.
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